Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria — Peoria, Arizona
+ 276 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
+ 115 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Locations: - Investigative Site US058 — Birmingham, Alabama
- Investigative Site US016 — Anchorage, Alaska
- Investigative Site US026 — Chandler, Arizona
+ 62 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Locations: - Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
- Local Institution - 0365 — Tucson, Arizona
- Highlands Oncology Group — Springdale, Arkansas
+ 46 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Locations: - Exelixis Clinical Site #43 — Birmingham, Alabama
- Exelixis Clinical Site #36 — Phoenix, Arizona
- Exelixis Clinical Site #42 — Tucson, Arizona
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Locations: - VA Loma Linda Healthcare System — Loma Linda, California
- Sutter Cancer Center Sacramento — Sacramento, California
- Rocky Mountain Cancer Centers — Denver, Colorado
+ 33 more sites in the U.S.
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Locations: - Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
- Hoag Mem Hosp Presbyterian — Newport Beach, California
- Baptist MD Anderson Cancer Institute — Jacksonville, Florida
+ 11 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Locations: - University of California, Los Angeles — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Hartford Healthcare — Hartford, Connecticut
+ 10 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Locations: - Investigative Site — Chicago, Illinois
- Investigative Site — Bethesda, Maryland
- Investigative Site — Boston, Massachusetts
+ 5 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Locations: - City of Hope — Phoenix, Arizona
- City of Hope — Duarte, California
- City of Hope — Chicago, Illinois
+ 3 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Locations: - Dana-Farber Cancer Institute — Boston, Massachusetts
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Taylor Cancer Research Center — Maumee, Ohio
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Locations: - Ventura Clinical Trials — Ventura, California
- Clavis Medical, LLC — Miami Lakes, Florida
- Beth Israel Deaconess Medical Center — Boston, Massachusetts